摘要:
The invention relates to modified proteins of the superfamily of “ubiquitin-like proteins”, proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.
摘要:
The invention relates to modified proteins of the superfamily of “ubiguitin-like proteins”, proteins that have a ubiguitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.
摘要:
The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.
摘要:
The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.
摘要:
The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.
摘要:
The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.
摘要:
The invention relates to modified proteins of the superfamily of “ubiquitin-like proteins”, proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.
摘要:
The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided.
摘要:
The present invention refers to novel recombinant proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B). Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component.
摘要:
The present invention is directed to a multimeric agent and a multimeric conjugate formed from this multimeric agent and a biologically active agent. Said multimeric conjugates have a longer life time in vivo and an increased avidity compared to the unmodified biologically agent. The present invention is further directed to a pharmaceutical or diagnostic composition containing said conjugate as well as to a method of its production. The invention additionally provides the use of said conjugates for the detection, determination, separation and/or isolation of a specific binding partner and for the diagnosis, prophylaxis and treatment of diseases in which the specific binding partner is directly or indirectly involved.